Dynavax Technologies Corp (DVAX) Common Stock USD0.001

Sell:$10.76Buy:$10.77$0.05 (0.47%)

NASDAQ:2.50%
Market closed | Prices delayed by at least 15 minutes
Sell:$10.76
Buy:$10.77
Change:$0.05 (0.47%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$10.76
Buy:$10.77
Change:$0.05 (0.47%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Key people

David F. Novack
President, Chief Operating Officer
Ryan Spencer
Chief Executive Officer, Director
Kelly MacDonald
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
John L. Slebir
Senior Vice President, General Counsel
Robert Janssen
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Scott D. Myers
Independent Chairman of the Board
Emilio Emini
Director
Lauren P. Silvernail
Director
Francis R. Cano
Independent Director
Julie Eastland
Independent Director
Click to see more

Key facts

  • EPIC
    DVAX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US2681582019
  • Market cap
    $1.28bn
  • Employees
    405
  • Shares in issue
    122.41m
  • Exchange
    NASDAQ
  • Index
    S&P 600 Small Cap, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.